AD-214 (Addpharma, Inc.)

AD-214 is an investigational fixed-dose combination (FDC) drug developed by Addpharma Inc. for the treatment of gastroesophageal reflux disease (GERD). It is composed of **rabeprazole**, a second-generation proton pump inhibitor (PPI), and **sodium bicarbonate**, which acts as an antacid and buffering agent. This formulation is categorized as an "incrementally modified drug" (IMD) designed to improve the stability and absorption of rabeprazole. Sodium bicarbonate neutralizes gastric acid, thereby protecting the acid-labile rabeprazole from degradation in the stomach and allowing for its absorption without the need for enteric coating. This mechanism potentially enables a faster onset of acid suppression compared to traditional enteric-coated PPI formulations. AD-214 has been evaluated in Phase 1 clinical trials to compare its safety, pharmacokinetics, and pharmacodynamics with other formulations, such as AD-2141, and individual components like rabeprazole.

Other names

AD-214 i-body-Fc fusion proteinAD214 i-body-Fc fusion proteinAD 214 i-body-Fc fusion proteinanti-CXCR4 i-body-Fc fusion proteinanti-CXCR-4 i-body-Fc fusion proteinanti-CXCR 4 i-body-Fc fusion protein